Last updated on March 2018

PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies

Brief description of study

The purpose of this study is to determine the safety and tolerability of weekly intravenous (IV) administration of XmAb14045 and to determine the maximally tolerated dose (MTD) after the first dose, and then to determine the MTD after second and subsequent infusions.

Clinical Study Identifier: NCT02730312

Contact Investigators or Research Sites near you

Start Over

Wendy Stock, MD

University of Chicago
Chicago, IL United States
  Connect »

Kasturi Ganesh Barki

The Ohio State University Comprehensive Cancer Center
Columbus, OH United States
  Connect »

Farhad Ravandi-Kashani, MD

MD Anderson Cancer Center
Houston, TX United States
  Connect »

Carol Fairchild, RN

Mayo Clinic Jacksonville Florida
Jacksonville, FL United States
  Connect »

Stacey Brown

Northside Hospital
Atlanta, GA United States
  Connect »

Raya Mawad, MD

Swedish Cancer Institute
Seattle, WA United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.